Thalidomide

Thalidomide, under the name of Thalidomide Pharmion is now commercially available in the UK.

Thalidomide Pharmion has been granted a licence for use in combination with melphalan and prednisolone as first-line treatment for patients with untreated multiple myeloma aged 65 years or over, or patients who are not eligible for high-dose chemotherapy.

Originally developed as treatment for insomnia and morning sickness in the 1950s, thalidomide has since been shown to be highly active against myeloma. It has immunosuppressive properties that appear to inhibit the growth and survival of myeloma cells, as well as inhibit the growth of new blood vessels.

To prevent exposure of pregnant women to thalidomide, healthcare professionals and patients are required to adhere to the measures specified in the Thalidomide Pharmion Pregnancy Prevention Programme. The programme links product supply to education of the prescriber, dispensing pharmacist and patient.

View Thalidomide Pharmion drug record

Further information: Celgene Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New secondary prevention approach backed for patients with stable cardiovascular disease

New secondary prevention approach backed for patients with stable cardiovascular disease

NHS prescribers have a new routine option for preventing...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...